Unraveling The Key Questions in EGFR-Driven NSCLC Treatment - Episode 2
FLAURA and FLAURA2: Key Efficacy and Safety Data
Panelists discuss how osimertinib monotherapy demonstrated robust progression-free survival and overall survival benefits in FLAURA, while FLAURA2 showed that adding chemotherapy to osimertinib further improved progression-free survival (PFS) although overall survival (OS) data remains immature, leading to ongoing debate about the optimal first-line approach.
Video Player is loading.
Video content above is prompted by the following:
- Please comment on the PFS and OS data for osimertinib monotherapy vs combination therapies in FLAURA and FLAURA2.
Related Content:
